Compare SON & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | BLCO |
|---|---|---|
| Founded | 1899 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.4B |
| IPO Year | 2014 | 2022 |
| Metric | SON | BLCO |
|---|---|---|
| Price | $50.79 | $15.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $60.13 | $18.45 |
| AVG Volume (30 Days) | ★ 1.3M | 426.6K |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | $5,101,000,000.00 |
| Revenue This Year | $0.10 | $8.65 |
| Revenue Next Year | $1.82 | $5.59 |
| P/E Ratio | $74.21 | ★ N/A |
| Revenue Growth | ★ 41.72 | 6.47 |
| 52 Week Low | $38.65 | $12.02 |
| 52 Week High | $58.44 | $18.92 |
| Indicator | SON | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 46.74 |
| Support Level | $46.53 | $15.20 |
| Resistance Level | $52.71 | $15.67 |
| Average True Range (ATR) | 1.50 | 0.38 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 73.13 | 53.81 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.